

ASX Announcement

Racura Secures Support from Specialist Institutional Investor

- Private Placement of 526,315 shares to a specialist institutional investor focused on emerging healthcare companies
- This nominal strategic placement enables the investor to establish an initial equity position in Racura
- The placement, combined with funds from the Piggyback and Bonus Options, has raised a total of \$31.2 million to support the clinical development of RC220

4 June 2026

Racura Oncology Limited (“Racura”) is pleased to advise that a specialist institutional investor focused on emerging healthcare companies has provided additional funding via a small, strategic private placement (Placement) that enables the investor to establish an initial equity position in the company.

The investor has provided a binding commitment to subscribe for 526,315 fully paid ordinary shares in Racura at an issue price of \$1.90 per share, a 23% discount to the average market price as of 3 June. No broker or other fees were paid in connection with this Placement, reducing the effective discount to 17%.

The new shares will be issued using the Company’s existing placement capacity under ASX Listing Rule 7.1.

The Placement of approximately \$1 million, combined with funds raised under both the Piggyback Options offer and Bonus Options offers, has raised a total of \$31.2 million to support the clinical development of RC220 and general working capital.

Chief Executive Officer and Managing Director, Dr Daniel Tillett, said: *“We are delighted to welcome this new institutional investor as a Racura shareholder. This investment reflects a growing institutional awareness of Racura, however, as the company is well financed by our existing shareholders, there has been no opportunity for interested institutions to invest. This nominal strategic placement enables this specialist investor to establish an initial equity position with minimal dilution to existing shareholders.”*

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura announcements please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Kitty O'Neill

kitty.oneill@irdepartment.com.au